CA
MRNA icon

Calton & Associates’s Moderna MRNA Stock Holding History

Calton & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,247
Closed -$865K – 395
2021
Q3 		$865K Sell
2,247
-862
-28% -$318K 0.19% 133
2021
Q2 		$731K Sell
3,109
-158
-5% -$28.2K 0.14% 157
2021
Q1 		$428K Buy
3,267
+9
+0.3% +$1.3K 0.08% 213
2020
Q4 		$340K Buy
3,258
+243
+8% +$24.6K 0.06% 233
2020
Q3 		$213K Sell
3,015
-664
-18% -$46.3K 0.04% 306
2020
Q2 		$236K Buy
+3,679
New +$201K 0.05% 267

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Calton & Associates's MRNA Position: Q4 2021 in Review

Calton & Associates sold out of Moderna (MRNA) in Q4 2021, closing a stake of 2,247 shares — an estimated $865K sold.

Calton & Associates first reported a position in MRNA in Q2 2020 and held it in 6 quarters. The position peaked at $865K in Q3 2021. 1,109 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

  • Calton & Associates reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
  • Calton & Associates sold 2,247 Moderna shares in Q4 2021, an estimated $865K.
  • Calton & Associates first reported a position in Moderna in Q2 2020 and held it in 6 quarters.
  • Calton & Associates's Moderna position peaked at $865K in Q3 2021.
  • 1,109 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Calton & Associates's 13F filing for Q4 2021, filed 13 Jan 2022.